Sixty-one patients were in the trial, each receiving a single injection of a Wnt-rebalancing drug directly into their knee. All sixty-one saw improvement. When researchers measured the impact of the drug six months later, they found less pain and greater mobility, including an average of nearly two millimeters of new cartilage.
